Nuvectis Pharma draws top biotech funds after $115M raise
What's the deal? Nuvectis Pharma (NASDAQ: NVCT) raised $115 million in a July follow-on offering, and newly filed institutional holdings reveal a roster of dedicated healthcare funds behind the round. Backers include Soleus Capital Management, Tang Capital ManagementDealroom has a profile for this one. Try Dealroom →, Perceptive Advisors, Avidity Partners ManagementDealroom has a profile for this one. Try Dealroom →, Alyeska Investment GroupDealroom has a profile for this one. Try Dealroom →, and Sphera Funds ManagementDealroom has a profile for this one. Try Dealroom →.
Why now? The financing followed a June 22 licensing deal with China's Haisco Pharmaceutical GroupDealroom has a profile for this one. Try Dealroom →, which gave Nuvectis ex-China rights to two clinical-stage assets, NXP100 and NXP200, for an upfront fee plus tiered milestones and royalties. Nuvectis priced the raise a week later, extending its cash runway into the first half of 2029.
Who's buying? Soleus, which builds concentrated positions in small and mid-cap biotech, crossed a 5% stake and now holds roughly 1.65 million shares. Tang CapitalDealroom has a profile for this one. Try Dealroom →, run by Kevin Tang, took 1,550,000 shares, while Perceptive Advisors — a long-term backer of Argenx and Rocket Pharmaceuticals — took a fresh 1,000,000-share position.
The ownership picture: Institutions now hold roughly 30% of shares outstanding, about double the level a quarter earlier, and insiders another 34%. BlackRock added more than 30% in the quarter to lift its stake past one million shares.
What's the endgame? Nuvectis is expanding into immunology with NXP100, a once-daily oral Complement Factor B inhibitor. It won approval in China in July 2026 for treatment-naive paroxysmal nocturnal hemoglobinuria, on the strength of a Phase 3 study against eculizumab.
The data: In that trial, 59.5% of NXP100 patients reached hemoglobin levels of at least 12 g/dL, compared with 8.3% on eculizumab. A second Chinese marketing application, for patients who failed C5 inhibitor therapy, is under review.
The signal: When healthcare-dedicated funds that run tightly held books take concentrated stakes in a clinical-stage biotech, it reads as conviction rather than passive allocation — and it points to growing investor appetite for the oral CFB inhibitor class.
Read more: Business Insider
Image credit: foteih
